收藏切换
Clinical analysis of efficacy and safety of ceftazidime/avibactam salvage treatment of carbapenem-resistant Klebsiella pneumoniae infection in premature infants
收藏切换
Kai FU1, Yonghui WANG1, Le KANG2, Jing ZHOU1, Yao MENG3, *, Xiaoling WANG3
World Clinical Drug | 2023, 44(4) : 331 - 336
Less
收藏切换
World Clinical Drug | 2023, 44(4): 331-336
• Article •
Clinical analysis of efficacy and safety of ceftazidime/avibactam salvage treatment of carbapenem-resistant Klebsiella pneumoniae infection in premature infants
Full
Kai FU1, Yonghui WANG1, Le KANG2, Jing ZHOU1, Yao MENG3, *, Xiaoling WANG3
Affiliations
  • 1.Department of Pharmacy, Zhumadian Central Hospital, Zhumadian 463003, Henan Province, China
  • 2.Department of Neonatal Intensive Care Unit, Zhumadian Central Hospital, Zhumadian 463003, Henan Province, China
  • 3.Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China
Published: 2023-04-10 doi: 10.13683/j.wph.2023.04.006
Outline
收藏切换
Objective

To evaluate the effect and safety of ceftazidime/avibactam (CAZ/AVI) in the salvage treatment of carbapenem-resistant Klebsiella pneumoni (CRKP) infection in premature infants.

Methods

Clinical data of 12 premature infants with CRKP infection who received salvage CAZ/AVI therapy from August 2020 to July 2022 were retrospectively analyzed. They were divided into combination group (n=5) and monotherapy group (n=7) according to whether CAZ/AVI was combined with meropenem or not. Clinical data, medication information, laboratory test results and adverse reactions of all infants were recorded.

Results

There were 5 cases of bloodstream infection and 7 cases of pulmonary infection. When delayed infusion of high dose meropenem or combined with fosfomycin was not effective, off-prescription CAZ/AVI salvage therapy was used, the average treatment time was (12.00±4.73) d, and the overall cure rate was 66.67%.

Conclusion

CAZ/AVI is effective and safe in the treatment of CRKP infection in premature infants, and can be used as an alternative treatment.

ceftazidime/avibactam  /  carbapenem-resistant Klebsiella pneumoniae  /  premature infant
付凯, 王永辉, 康乐, 周静, 孟瑶, 王晓玲. 头孢他啶/阿维巴坦挽救性治疗早产儿耐碳青霉烯类肺炎克雷伯菌感染的效果及安全性病例分析. 世界临床药物, 2023 , 44 (4) : 331 -336 . DOI: 10.13683/j.wph.2023.04.006
Kai FU, Yonghui WANG, Le KANG, Jing ZHOU, Yao MENG, Xiaoling WANG. Clinical analysis of efficacy and safety of ceftazidime/avibactam salvage treatment of carbapenem-resistant Klebsiella pneumoniae infection in premature infants[J]. World Clinical Drug, 2023 , 44 (4) : 331 -336 . DOI: 10.13683/j.wph.2023.04.006
Year 2023 volume 44 Issue 4
17
5
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2023.04.006
  • Receive Date:2022-09-21
  • Online Date:2026-11-18
  • Published:2023-04-10
Article Data
Affiliations
History
  • Received:2022-09-21
Affiliations
    1.Department of Pharmacy, Zhumadian Central Hospital, Zhumadian 463003, Henan Province, China
    2.Department of Neonatal Intensive Care Unit, Zhumadian Central Hospital, Zhumadian 463003, Henan Province, China
    3.Department of Pharmacy, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing 100045, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2023.04.006
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT